Bioventus Profit Margin

The latest profit margin for BVS is 9.36% as of June 2026. That compares with -0.03% in the prior-year period — up 33521.9% year over year. That is below the Healthcare sector average of 9.71%. Investors often review this figure alongside Bioventus's historical trend and sector peers before judging valuation or financial health.

Over the past year, BVS's profit margin moved from -0.03% to 9.36% — a 33521.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bioventus's valuation or profitability profile.

Against Healthcare companies, BVS currently prints 9.36% for profit margin, while the sector average sits near 9.71%. That is roughly 3.6% below the sector mean. Large gaps often invite a closer look at Bioventus's growth, margins, and balance sheet.

Profit Margin shows how effectively Bioventus converts resources into returns. At 9.36%, BVS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -0.03% in the prior-year period — up 33521.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BVS's profit margin (9.36%), review year-over-year change from -0.03%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.